Kyowa Kirin Stops Development of Skin Condition Treatment

Kyowa Kirin stops development of skin condition treatment

Kyowa Kirin on Tuesday said it is discontinuing all ongoing trials of its experimental drug to treat ​skin conditions after the company concluded that the potential risks ‌may outweigh the benefits for patients.

Kyowa Kirin Announces Discontinuation of Rocatinlimab Clinical Trials

TOKYO AND PRINCETON, Japan and the U.S., March 03, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the discontinuation of all ongoing clinical trials for rocatinlimab, an investigational anti-OX40…

Kyowa Kirin discontinues ongoing trials of rocatinlimab

Kyowa Kirin has announced the global discontinuation of all ongoing clinical trials for rocatinlimab, an anti-OX40 monoclonal antibody under investigation for moderate-to-severe AD, prurigo nodularis, and moderate-to-severe asthma.The post Kyowa Kirin discontinues ongoing trials of rocatinlimab appeared first on Clinical Trials Arena.

Kyowa Kirin ends OX40 trials after Amgen balked and more safety concerns arose

Kyowa Kirin is ending all clinical trials of rocatinlimab, its experimental anti-OX40 antibody that Amgen walked away from earlier this year, after additional safety concerns arose in recent weeks. The Tokyo-based drug ...